BB Biotech reported a net loss of 21 million francs in Q1 2026, a substantial improvement from the 241 million loss in the same period of 2025, attributed to a stronger portfolio and better market conditions. The company experienced a positive return on share price, outperforming the Nasdaq Biotechnology Index across multiple currencies, and narrowed its share price discount to net asset value. The portfolio saw active repositioning, increasing from 24 to 30 investments, including entry into new sectors like oncology and rare diseases. Notably, Terns Pharmaceuticals was acquired by Merck, highlighting strong demand in the biotech sector amidst global uncertainties.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.finews.com/news/english-news/71983-bb-biotech-ergebnis-q1-2026-healthcare-biotechnology-assetmangement-finanzplatz-schweiz-2
